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Abstract 
Life expectancy and the number of elderly people are progressively increasing around the world. Together with other 
pathologies, allergic diseases also show an increasing incidence in geriatric age. This is partly due to the growing 
emphasis on a more accurate and careful diagnosis of the molecular mechanisms that do not allow to ignore the real 
pathogenesis of many symptoms until now unknown, and partly to the fact that the allergic people from 20 years ago 
represent the elderly population now. Moreover, environmental pollution predisposes to the onset of allergic asthma 
and dermatitis which are the result of internal pathologies more than the expression of allergic manifestations. At 
the same time the food contamination permits the onset of allergic diseases related to food allergy. In this review we 
provide the state of the art on the physiological changes in the elderly responsible for allergic diseases, their biologi-
cal characteristics and the major immunological and extra immunological mechanisms. Much emphasis is given to 
the management of several diseases in the elderly, including anaphylactic reactions. Moreover, some new features are 
discussed, such as management of asthma with the support of physical activity and the use of the AIT as prevention 
of respiratory diseases and for the purpose of a real and long lasting benefit. The mechanisms of adverse reactions to 
drugs are also discussed, due to their frequency in this age, especially in polytherapy regimens. Study of the modifica-
tions of the immune system is also of great importance, as regards to the distribution of the lymphocytes and also the 
presence of a chronic inflammatory disease related to the production of cytokines, especially in prevision of all the 
possible therapies to be adopted to allow an active and healthy aging.
Keywords: Aging, Elderly, Allergy, Conjunctivitis, Asthma, Immunotherapy, Urticaria, Drug reaction, Anaphylaxis, Food 
allergy
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The aging population in Europe and all over the world 
implicates increasing social problems and a specific sci-
entific support is by now as required in order to ensure 
what is called a “successful aging”. In fact, epidemiologi-
cal data attest always more the need for a healthy aging 
to contain the increased economic burden for assistance 
of a growing number of people over 65 in condition of 
“fragility”. Aging is an unavoidable, universal, complex 
process characterized by progressive loss of functional 
reserves and reduction of the capability to adapt to the 
environment. This biological phenomenon derives from 
an interaction between genetic and environmental fac-
tors. Healthy lifestyle and favorable environment allow 
genetically predisposed subjects to reach extreme lon-
gevity and maintain acceptable health status and auto-
sufficiency [1].
Disfunctions of the immune system are the basis 
of many disabling diseases that occur during aging, 
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including neurodegenerative and cardiovascular diseases, 
whose appearance is due to the state of proinflammatory, 
also called “inflamm-aging”, that is typical of the elderly 
[2]. The mechanisms that enable a “successful” aging are 
related to certain physical and immunologic conditions. 
This is due to multiple factors, including the increased 
pollution; moreover the allergic pediatric population that 
was born 50–60 years ago has reached the age of senes-
cence. Therefore, diseases such as food allergy, urticaria, 
allergic reactions to drugs, and anaphylaxis are becoming 
more frequent in the elderly population [3].
The purpose of this work is to provide the state of the 
art on the physiological changes in the elderly responsi-
ble for allergic diseases, their biological characteristics 
and the major immunological and extra immunological 
mechanisms.
Lymphocyte subpopulations in the elderly
Most information on lymphocyte subpopulations and 
their changes occurring with age derive from the cyto-
fluorimetric analysis using monoclonal antibodies 
directed to surface antigens of gated lymphoid cells col-
lected from peripheral venous blood. It is well known 
that the total number of lymphocytes—the main circulat-
ing subset of leukocytes in the first years of life declines 
since young adulthood and then reaches very low num-
bers from age 60 onwards. And it is also known that 
usually about 2% of all lymphocytes appear to recircu-
late in the blood, while the remaining are resident in gut 
and spleen or circulate through all the lymphoid system 
(lymph nodes, mucosal aggregates, thoracic duct, tonsils 
etc.). Therefore our assumption is that the blood circu-
lating 2% should reflect the proportion of lymphocyte 
subpopulations really present in the entire body. This can 
be true for some (e.g. γ/δ T cells, NK T cells, CD8 αα, 
and many others), but not all subsets, because some are 
strictly compartmentalized mainly to the mucosa. The 
main lymphocyte subpopulations discussed briefly here 
will be T subsets, B cells and innate immunity.
At birth high numbers of B cells are present, and low 
NK cells, and they will change in opposite directions dur-
ing the individual’s lifetime. T cells are generated through 
thymic selection and the entire repertoire is established 
by the 10th  year of life, while the thymus will undergo 
progressive involution from the age of 30. T cells rep-
resent the major subset (55–70% of all lymphocytes) in 
young people and so remain until late age. However the 
two main T cell subsets, identified by the coreceptor 
molecules CD4 and CD8, show different changes with 
ageing, with a progressive increase of CD8+ cells with 
advancing age.
CD4+ and CD8+ peripheral blood T lymphocytes 
show mutually exclusive expression of CD45RA or 
CD45R0, two isoforms of the common leukocyte anti-
gen that help recognize respectively virgin/unprimed and 
memory/activated T cells [4]. Changes in the subsets have 
been observed with age: at birth 95–99% of the CD3+ T 
lymphocytes expressed the CD45RA isoform, while an 
increase of CD45R0+ cells was observed until 30 years. 
Nonetheless, in very old age a proportion of CD45RA+ 
among CD4+ cells was still present (about 20%) and even 
more in CD8+ lymphocytes (up to 40–50%). These data 
originate from very selected subjects without chronic 
common pathologies or taking drugs able to affect the 
blood subpopulations. The reverse “frail” or disabled 
condition can lead to different observations, with many 
older subjects showing many more CD8+ and “memory” 
phenotypes. These considerations lead to analyze the 
presence and role of thyme in older age. The generation 
of new T cells is indeed crucial to maintain a functional 
immune system, and lymphocytes defined “recent thymic 
emigrants”, as well as the detection of the so called “T cell 
receptor rearrangement excision circles (TREC)”, have 
been studied [5], leading to the conclusion that new T 
cells are produced even in old age, although in very low 
numbers. Molecules able to stimulate thymic produc-
tion include cytokines like interleukin (IL)-7, IL-15 and 
others. The level of expression of the interleukin 7 recep-
tor (IL-7R) gene in blood has recently been found to be 
associated with familial longevity and healthy ageing [6]. 
IL-7R is crucial for T cell development and important for 
immune competence.
The increased CD4:CD8 ratios in the elderly were sig-
nificantly lower in Cytomegalovirus (CMV)-seropositive 
individuals, that in our experience represent >98% of 
aged subjects. This study also showed a lower naïve and 
a larger late-differentiated compartment of CD8+ αβ 
T-cells. Longitudinal studies suggest that accumulation 
of these cells is a dynamic process as an age-associated 
change [7].
A coincevable hypothesis is that these events are at 
least partly due to the effects of the maintenance of 
essential immune surveillance against persistent viral 
infections, notably CMV, which may exhaust the immune 
system over time, as shown in the NONA immune lon-
gitudinal study [4]. From this and other analysis an 
immune risk profile (IRP) was identified, defined by an 
inverted CD4/CD8 ratio and associated with persistent 
cytomegalovirus infection and increased numbers of 
CD8+ CD28− cells, which led to a relative 6-year sur-
vival in NONA individuals.
As regards the functional characteristics of these T cell 
compartments in the elderly, exhausted or non-func-
tional CD8+ cells have been described in several stud-
ies. T cell clones (TCC) of two healthy centenarians were 
studied and compared them with TCC obtained by three 
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young normal subjects: totally 180TCC were analyzed. 
In young donors, 35TCC were CD4+, 56 CD8+ and 
two were alpha beta +CD4−CD8− (double negative). 
In centenarians, 46CD4+TCC, 38CD8+, 2CD4+CD8+ 
(double positive) and 1 gamma delta+ double negative 
were obtained [8]. The cytokine analysis showed that the 
Th profiles of CD8+TCC are nearly overlapping in two 
groups, whereas a major shift from a Th1 to a Th0 pattern 
is shown by CD4+TCC.
It is well known that T cells from aged subjects have 
a reduced ability to produce IL-2, but other functions 
seem to be upregulated, since IL-1, IL-4, IL-6 and TNFα 
production are increased. These cytokines are known 
to control B cell differentiation, through isotype switch 
and Ig production. A significant age-related increase of 
the serum level of immunoglobulin classes (IgG and IgA 
but not IgM) and IgG subclasses (IgG1, 2 and 3, but not 
IgG4) is detected [9]. An age-related decrease of circulat-
ing B cells occurs in parallel. The impairment of primary 
responses to immunization, and other aspects of humoral 
immunity, including mucosal responses, autoantibody 
production led to the hypothesis of a complex derange-
ment of B cell function and/or compartmentalization 
with age. Unusual IgD(−)CD27(−) double-negative B 
cell population was described in the elderly [10]. Most of 
these were less functional memory B cells, so it is specu-
lated these were also late memory or exhausted cells that 
have down-modulated the expression of CD27 and filled 
the immunologic space in the elderly.
Finally, also adaptive immunity undergoes severe dete-
rioration with age and represents the main problem in 
the elderly. Evidence accumulated over the last decade 
supports the hypothesis that aging also has a profound 
impact on innate immunity, including reduced or dys-
functional NK lymphocytes, which in turn markedly 
affects the health and longevity of older people [11].
The role of cytokines in the elderly
Aging is a dynamic process characterized by a continu-
ous remodeling sustained by DNA repair, apoptosis, 
immune response, oxidative stress and inflammation. 
To reach extreme longevity, it is necessary for all these 
mechanisms to interact in an efficient way. The theory of 
inflammaging focuses on the activation of a subclinical, 
chronic low-grade inflammation that occurs with aging. 
It is a manifestation of immunosenescence, which is the 
sum of changes affecting the functionality of the immune 
system in elderly.
A major contributor of inflammaging is the antigenic 
load of persistent infection which starts from intrau-
terine life and continues for an entire lifespan. The 
pro-inflammatory phenotype of senescent cells pro-
tects against infectious diseases but, at the same time, 
contributes to inflammaging, as large quantities of pro-
inflammatory cytokines are produced/released in order 
to repair tissue damage [12]. Many age-related diseases 
share an inflammatory pathogenesis; moreover, the acti-
vation of inflammatory pathways appears to be involved 
in the pathophysiology of sarcopenia and frailty. Long-
lived people, especially centenarians, seem to cope with 
chronic subclinical inflammation through an anti-inflam-
matory response, called therefore “anti-inflammaging” 
[13]. We believe that if inflammaging is a key to under-
stand aging, anti-inflammaging may be one of the secrets 
of longevity.
Circulating cytokines are involved both in inflamma-
tion and anti-inflammation, and are the expression of a 
system that involves genes and environment.
Proinflammatory cytokines in aging
The most relevant proinflammatory cytokines involved 
in aging processes are interleukin (IL)-1, IL-6, tumor 
necrosis factor (TNF) and interferon (IFN)-γ. High lev-
els of these cytokines are associated with increased risk 
of morbidity and mortality in the older subject. In par-
ticular, IL-1 is involved in the alteration of nutritional sta-
tus, in cognitive decline, and development of Alzheimer’s 
disease [14] and as a risk factor for depressive symptoms 
in aged people [15]. IL-6 and TNF serum levels influence 
the onset of frailty, poor physical performance, loss of 
muscle strength, cognitive decline, cerebrovascular and 
cardiovascular events [14, 16]. These cytokines are also 
closely linked to the genesis of cancers (IL-6), to cardiac 
remodeling in heart failure [14] and to the risk of com-
munity-acquired pneumonia requiring hospitalization 
(both IL-6 and TNF) [17].
An increase of intracellular IFN-γ, together with other 
type 1 cytokines, within three CD8+ T subsets (naïve, 
effector/cytotoxic and memory) was observed in aged 
subjects [18]. Conversely, the % age of IFN-γ positive cells 
significantly decreased in a virgin CD4+ subset as well as 
in activated/memory T cells from old subjects [19]. How-
ever, in a study on nonagenarians, IFN-γ plasma levels 
are unmodified compared to young controls, suggesting a 
substantial maintenance of relevant T cell functions [20].
Another potent proinflammatory cytokine that plays 
a relevant role in aging is IL-18. A recent study showed 
that IL-18 is a predictor of mortality for heart failure in 
a group of octogenarians. A study of follow-up (of mean 
2.4 years) underlighted that subjects who died for heart 
failure had higher serum values of IL-18 compared with 
those still alive [21]. IL-18 serum levels increase with age-
ing [22], but at the same time longevity is characterized 
by a reduced incidence of ischemic events.
Our group evaluated serum levels of IL-18 
and IL-18 binding protein (IL-18BP) in healthy 
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centenarians, younger healthy controls and patients with 
chronic ischemic cardiac disease. Centenarians showed 
significantly higher levels of IL-18 and IL-18BP com-
pared to each control group. Elevated IL-18 levels were 
also present in patients with chronic ischemic syndrome; 
centenarians exhibited a lower level of free IL-18 than 
chronic ischemic patients. These results indicate that 
inactivation of IL-18 by IL-18BP may explain the appar-
ent paradox of high serum levels of IL-18 in centenarians, 
without signs of vascular diseases [23].
Significant increased IL-12 serum levels were found in 
nonagenarians compared to young controls; this might 
be related to the increase of NK cell functions character-
izing aging processes [20]. Different data were shown by 
other authors [24] who found that age was not correlated 
with Toll-like receptor (TLR)-mediated IL-12 and IL-23 
production after stimulation of whole blood cells. In 
contrast, poor nutritional status and frailty and not age 
by itself were associated with decreased IL-12 and IL-23 
production. These results in frail, elderly patients could 
account for their susceptibility to many pathogens [24].
In a study of our group centenarians subjects showed 
significantly higher IL-15 levels compared to both young 
and old controls [25]. These findings may explain, at least 
in part, the characteristic increase of memory cells in 
elderly subjects and may lead to a better understanding 
of the capacity of adaptation to the environment of cen-
tenarians, defending themselves from infections through 
immune-inflammatory responses.
We also found increased IL-22 serum levels in older 
patients with chronic heart failure [26] and in healthy cen-
tenarians [27]. In particular, only the II and III NYHA class 
had IL-22 values significantly higher than the controls, 
whereas there was no difference between the IL-22 levels 
of NYHA class IV and the controls [26]. The reason may 
be the decline of immune function in patients with chronic 
heart failure. In fact we can hypothesize that the reduction 
of IL-22 levels with the progression of NYHA class can 
be responsible of the impaired ability of these patients to 
respond to infections, as IL-22 has anti-microbial proper-
ties [26]. Therefore, it is likely that the pro-inflammatory 
condition sustained by IL-22 is protective against infection, 
promoting the longevity of these subjects [27]. It might be 
speculated that under certain circumstances the activity of 
this cytokine against infection may be more relevant to sur-
vival than its potential negative impact on inflammation.
The data on IL-2 in long-lived people are controversial. 
An age-related decrease in IL-2 production by stimulated 
PBMC or lymphocytes and IL-2 serum levels has been 
reported [28–33]. Other authors found that intracellular 
production of IL-2 showed a progressive age-dependent 
increase in CD8+ T cells [18]. However, in other studies, 
serum IL-2 levels were unmodified in healthy aged peo-
ple [34] and centenarians [20].
Anti‑inflammatory cytokines in aging
Among anti-inflammatory cytokines IL-10 plays a central 
role. High levels of this cytokine in whole blood samples 
were found to be associated with successful aging and, 
particularly, with a markedly reduced risk of death from a 
cardiovascular event in aged people [16], but diminished 
resistance to infectious diseases [35]. High levels of IL-10 
have been found in centenarians; this condition may 
result in protection from cancer [36].
IL-10 production is tightly regulated and several single 
nucleotide polymorphisms controlling production have 
been described. IL-10 low-producer genotypes seem to 
play a particular role in susceptibility to inflammatory 
diseases, together with age-related ones, whereas IL-10 
high producer genotypes are involved in longevity [37].
Studies on IL-10 polymorphisms showed different 
results between males and females [reviewed in 38]. For 
this reason it seems that gender is a major variable in 
the genetics of longevity and that men and women prob-
ably follow different strategies to reach it. Discordant 
results on the association between IL-10 polymorphisms 
and longevity have been obtained in other populations. 
Therefore, cytokine/longevity associations have a popu-
lation-specific component, being affected by the popu-
lation-specific gene pool as well as by gene-environment 
interactions, behaving as survival rather than longevity 
genes [39].
IL1-Ra can be considered a significant predictor of 
mortality in elderly. A prospective population-based 
study, including 285 nonagenarians, demonstrated that 
plasma levels of IL-1Ra were higher in subjects who 
died during a 4-year follow-up than in those who sur-
vived [40]. However, another study on 1131 elderly Ital-
ians showed a significant age-related increase of IL-1Ra 
plasma levels. In long-lived individuals, this seems to be 
a safeguard mechanism to cope with the age-associated 
increased inflammatory state [41].
Contrasting data emerge from studies about the role of 
IL-4 on aged and long-lived people. Some authors [20] 
found a reduction of IL-4 serum levels and an increase of 
IL-13 in a group of nonagenarians, mirroring the main-
tenance of some effector mechanisms of the immune 
response in advanced ages. On the contrary, other 
authors [18], found that type 2 intracellular cytokines, 
including IL-4, increased within virgin, memory and 
effector/cytotoxic CD8+ T cells in aged people.
Another study determined IL-4 production in three 
CD4+ T-subsets—virgin, activated/memory, and effec-
tor/memory—at different ages. IL-4 positive cells 
appeared to increase, with age. In particular, IL-4 positive 
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cells significantly increased in activated/memory T cells 
from nonagenarian subjects. The authors also found a 
statistically significant decreased ratio of IFN-γ/IL-4 
within activated/memory T cells in old people in com-
parison with young people. These data suggest a dynamic 
shift towards an increased role of type 2 cytokines and 
a diminished role of type 1 cytokines in human ageing. 
However, it is important to remember that this phenom-
enon, which could be interpreted as a compensatory 
mechanism to the increased pro-inflammatory status, 
occurs within a background where type 1 cytokines are 
quantitatively dominant [19].
Also data reported on correlation between TGF-β 
levels and age are contrasting. A study reported serum 
TGF-β1 levels inversely associated with age [42]. How-
ever, high levels of TGF-β have been found in a group 
of octogenarians and nonagenarians [43] and in two 
different groups of centenarians [36, 44]. This condi-
tion suggests that TGF-β could both counteract and 
counterbalance the harmful effects of inflammaging and 
may result in protection from cancer. A recent study did 
not detect any differences in serum levels of TGF-β and 
TGF-β mRNA levels from PBMCs between young and 
old women [45].
Longevity is characterized by a balance between pro-
inflammatory and anti-inflammatory agents, which act 
as key players. A pro-inflammatory tendency can confer 
high resistance against infectious diseases but, on the 
other hand, may increase susceptibility to inflammation-
based diseases throughout life. An anti-inflammatory 
trend, instead, may cause an increased susceptibility to 
infections in pre-reproducing life and might not allow 
attainment of old age. The currently available knowl-
edge is of great importance, but not sufficient to explain 
the secret of longevity. Data reviewed in this work are 
sometimes conflicting. The reason for the discrepancy is 
unknown, however, several factors may be involved, such 
as ethnic, lifestyle, cultural and genetic differences among 
the populations analyzed.
The studied populations are very heterogenic, the 
cohorts of patients present discrepancies and are not 
comparable. Some works were performed on healthy 
aged people, other works enrolled people only consid-
ering age, without considering health status and with-
out selecting people for pathologies. Furthermore, it is 
known that low-grade inflammation is also associated 
with conditions such as obesity, diet, smoking, and physi-
cal inactivity. Therefore the balance between life style and 
physiological changes during aging on one hand and risk 
factors for age-associated diseases on the other should be 
taken into consideration.
However, despite all these controversial data regard-
ing the clinical relevance of different cytokines, several 
studies have assigned a pivotal role in inflammatory or 
anti-inflammatory processes to some mediators.
According to a perspective suggested in recent years, 
the best candidates to become centenarians are not the 
strongest and most robust subjects among their age 
cohort, but subjects that better adapt to the environment, 
showing more biological plasticity. Some characteristics 
emerged among this group of exceptional individuals: 
better control of oxidative stress and remodeling of the 
immune system with intense anti-inflammatory activity.
Low-grade chronic inflammation is characteristic of 
aged people and centenarians, but long-lived are also able 
to avoid the main age-related diseases, thanks to the con-
trasting action of anti-inflammatory agents [46].
Climate change and influence on elderly allergic diseases
There is a strong correlation between global warming 
and greenhouse gases and the worst estimates of the past 
about it were completely overcome.
The principal determinant of global warming is 
increasing concentration of air pollutants, as underlined 
by a report of World Health Organization (WHO) [47]. 
Last report of European Environment Agency stated that 
up to 96% of the European Union’s urban population is 
currently exposed to fine particulate matter (PM) at con-
centrations higher than those recommended in WHO 
guidelines [47]. Furthermore, increased temperatures 
are reported as extreme events for seasonal allergy: ris-
ing temperatures recorded in recent years cause elon-
gation and anticipation of the pollen season, increased 
pollen production, spread of invasive species. Increase of 
temperature and solar irradiation, associated with ozone 
gas and particulates, determines the formation of PM, 
including coarse (PM10) and fine (PM2.5) [48]. In normal 
ambient conditions PMs are a mixture of coarse (2.5–
10 μm), fine (<2.5 μm) and ultrafine particles (<0.1 μm), 
derived from different processes, with variable chemical 
matters. It should also be noted that, although ultrafine 
fraction accounts for less than 1% of PM mass, it repre-
sents the greatest part in terms of number of particles 
(typically >80%) [49]. This mixture of PM causes inflam-
matory effects on bronchial mucosa, increasing the risk 
of asthma and the number of exacerbations in subjects 
with bronchial hyper reactivity [50]. PMs are directly 
involved also in cardiovascular diseases, including vaso-
motor and cardiac autonomic dysfunction. Moreover, 
hemostatic unbalance, oxidative stress and inflammatory 
responses have been shown to contribute to the short-
term and long-term adverse effects of pollution exposure 
[51]. The exposure to ozone and to fine PM (PM2.5) can 
cause adverse health effects, including premature mortal-
ity due to cardiopulmonary diseases and/or lung cancer; 
recent studies highlighted that mortality rates due to air 
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pollution are different according to geographical area, 
suggesting region-specific air pollution control strategies 
[52].
Mechanism responsible of health effects
Pathogenetic mechanisms of PM on health effects are 
yet matter of controversy [53], in fact atmosphere is the 
medium of transit for a wide variety of biogenic parti-
cles. Among biogenic particles, the bio aerosol consists of 
very different types of particles, such as viruses, bacteria, 
mold, plant fibers or pollen, with a wide distribution in 
size (from nanometers to a few 100 μm). These phenom-
ena are able to activate several inflammatory mediators 
in respiratory tract directly acting on respiratory mucosa 
and indirectly promoting increase in pollens and air pol-
lutants concentration, with consequent effects on allergic 
and respiratory diseases [54].
The PM pollutants from sources such as hydrocar-
bons, volatile organic compounds and heavy metals 
can generate oxidants products. Organic compounds 
generate an oxidative stress through redoxing cycle of 
quinone-based radicals, complexing of metal result-
ing in electron transport and depletion of antioxidants, 
secondary to chemical reactions between quinones and 
thiol-containing compounds. Metals directly support 
electron transport to generate oxidants, with simultane-
ously decreasing of antioxidants. In addition, to direct 
generation of oxidants by organic and metal components, 
cellular responses contribute to oxidative stress: reactive 
oxygen species (ROS) production occurs in mitochon-
dria, cell membranes, phagosomes and endoplasmic 
reticulum. Oxidative stress following PM exposure deter-
mines a series of cellular reactions that includes activa-
tion of kinase cascades and transcription factors and 
release of inflammatory mediators, which eventually lead 
to cell injury or apoptosis. Consequently, oxidative stress 
is a central mechanism by which PM exposure leads to 
injury, disease and mortality [55]. Furthermore, exposi-
tion to diesel exhaust particles and ozone in human con-
trolled trials illustrated the important role of pollutants 
in immunopathogenesis of both allergic mechanisms and 
immune responses in airway diseases, such as asthma 
[56].
Influence of environment in elderly allergic diseases
Further findings show that some populations, especially 
the elderly, are particularly sensitive to short-term ozone 
exposure [57], with an higher risk of PM–associated hos-
pitalization death for this population [58].
As regards the impact of pollutants on the respiratory 
pathologies affecting older people, some data suggest 
a possible role of a changed immune response as it has 
been demonstrated in individuals during senescence [53]. 
Although, atmospheric pollution plays a major role in 
all age groups’ health [59, 60]. For example, it is known 
that, in older asthmatic patients, traffic pollution expo-
sure is the strongest predictor of poorer asthma-related 
QoL [61] and high daily exposure, together with obesity 
and not-atopic status, is associated with poorer asthma 
control [62]. It is also documented that mortality and 
risk of hospitalization in this population is increased dur-
ing more intense and longer-lasting heat wave periods. 
Peaks of mortality and hospitalization not only coincide 
with the day with highest temperature of the heat wave, 
but also could persist for the 5 subsequent days [63]. 
Furthermore, in another study, cardiovascular and res-
piratory diseases were analyzed in an elderly population 
of Moscow, as they are also related to air pollution and, 
in generally, are considered as major causes of hospital 
emergency admissions [64].
Recently, many studies focus on the potential mecha-
nisms of air pollution in inducing cardiopulmonary 
diseases. In fact, air pollution seems to be associated 
with increased plasma viscosity, abnormality of auto-
nomic function of the heart, including increased heart 
rate, decreased heart variability and increased cardiac 
arrhythmias [65]. These findings provide possible path-
ways in which air pollution affects cardiovascular sys-
tem. Pollutants can indeed induce oxidative processes in 
mitochondria, apoptosis or necrosis of macrophages and 
respiratory epithelial cells, resulting in decrease of host 
defense to respiratory infections and in increase of res-
piratory tract reactivity [66]. Moreover, patients with res-
piratory diseases, such as chronic obstructive pulmonary 
disease, often have a systemic defect in their antioxidant 
defenses and air pollution could cause significant addi-
tional oxidative stress as response to lung inflammations 
[67].
Nowadays health impact derived from climate change 
in Europe do not regard vector-borne infectious dis-
eases. In fact, geographical areas of several vector-borne 
diseases and/or of their vectors are already changing in 
altitude, as result of global warming. Mosquito-borne 
parasitic and viral diseases are among those diseases 
most sensitive to climate. In addition, more intense 
weather events create advantageous conditions for infec-
tious diseases. For example, heavy rains permit a bet-
ter survival of insect breeding sites, drive rodents out 
from burrows and can contaminate clean water systems 
[68–71].
Climate changes have an impact on health due to 
increases in temperature, which is amplified in central 
parts of the cities (heat island), with a significant impact 
on the health of the resident population, especially for 
elderly and people with cardio-respiratory disease (in 
particular asthma and COPD). Elevated temperature 
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reduced attendance of public areas and meeting points, 
such as parks or gardens. Some conditions can worsen 
this situation, i.e. elderly and/or subjects with chronic 
diseases, those with lower income, lonely subjects, immi-
grants and people with poor housing conditions. The 
reduction in hospital emergency admissions after the 
implementation of interventional programs supported 
the hypothesis of causal link between air pollution and 
diseases [70].
Recently, the Task Force of Air pollution and Climate 
Change of Italian Society of Allergy, Asthma and Clini-
cal Immunology proposed a National Health Program 
to support the public administration of cities. In fact, it 
is possible to create gardens and parks with not allergic 
pollen plants, as suggested in different studies [71]. This 
aspect is important because the public gardens in our 
cities are visited by many children and elderly every day. 
In sunny and wind days this population is exposed to 
numerous pollens and the presence of allergen pollens.
In conclusion, the effect of global warming on health is 
documented in many documents, where the major warn-
ings come from increased concentration of air pollution. 
In particular, urban population is currently exposed to 
fine PM concentrations, representing a daily problem for 
fragile population as elderly. Association among age, air 
pollution and climate changes were observed, confirming 
the particular interest in this population. Although, fur-
ther studies are necessary to define better how air pollu-
tion and climate change are mainly responsible in elderly 
allergic diseases.
Allergic conjunctivitis in the elderly
Although the eye was reported to be the first organ 
involved in the allergic reaction of the first described case 
of hay fever almost 200 years ago, ocular allergy has never 
received the same attention that has been given to respir-
atory and skin allergy [72]. On the other hand, in view of 
the peculiar anatomy and the prominent representation 
of the immune system in the ocular tissues, the eye has 
always represented an extremely useful model to study 
the immune and allergic response to environmental and 
endogenous stimuli [73]. There are several reasons for 
ocular allergy being considered the “Cinderella” of aller-
gic diseases, despite the fact that eye involvement repre-
sents one of the major causes of poor quality of life and 
may often be serious enough to affect vision. At first, it 
is the attitude of allergists to focus mainly on respiratory 
and skin manifestations, considering the eye symptoms 
only a complication of rhinitis, under the arguable defi-
nition of rhinoconjunctivitis. Secondly, the involvement 
of ocular tissues in several autoimmune and systemic 
diseases has often been thought to be prominent compe-
tence of other medical disciplines, such as rheumatology 
and internal medicine. At last, the prevalent surgical 
commitment of many ophthalmologists has so far made 
difficult a proper collaboration with allergists to focus on 
diseases commonly considered of minor priority in both 
pharmacological and clinical research and practice.
The spectrum of atopic eye diseases encompasses sea-
sonal allergic conjunctivitis (SAC), perennial allergic 
conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), 
atopic keratoconjunctivitis (AKC), atopic blepharo-
conjunctivitis (ABC), and giant papillary conjunctivitis 
(GPC). Common to these diseases are a papillary con-
junctivitis and, with the exception of GPC, evidence of 
a type I, IgE-mediated, hypersensitivity response [74]. 
Although each entity has unique immunopathogenic 
pathways, these conditions have all been described as 
chronic allergic conjunctivitis (CAC).
Life expectancy around the world is growing and it has 
been reported that by 2030 people over 65 will reach 20% 
of the total population [75]. In recent years, increasing 
attention has been dedicated to the evaluation of aller-
gic diseases in the elderly, often underdiagnosed and 
confused with signs and symptoms of the physiological 
physical and functional deterioration with age, as well as 
of their impact on well-being and quality of life [3]. How-
ever, very few data are available in literature regarding 
the prevalence, the role and the management of allergic 
conjunctivitis in the aged population [76]. Most of the 
reported evidence, in fact, relates to contact conjunctivi-
tis, often associated with drug use and due to impaired 
lacrimation in this particular population subset. How-
ever, although allergic conjunctivitis affects mainly chil-
dren and young adults, an increasingly number of cases 
is being diagnosed in the elderly. Atopic keratoconjunc-
tivitis seems to be the most commonly observed clinical 
picture and is therefore addressed in details below.
AKC was first described by Hogan in a group of highly 
atopic patients who developed chronic conjunctivitis, 
progressive corneal vascularization and scarring [77].
Currently, there is no agreement about the diagnostic 
criteria for AKC [78]. One proposed definition states that 
AKC is a chronic ocular surface non-infectious inflam-
matory condition, always associated with other atopic 
diseases (typically atopic dermatitis, but also periocular 
eczema, asthma, or rhinitis), occurring at any time in the 
course of the associated atopic disease independently 
from its degree of severity and with evidence of corneal 
involvement.
The pathogenesis of AKC involves the production of 
various cytokines by effector cells which are still under 
investigation, as their immunopathogenic roles are 
not fully understood. The main effector cells in AKC 
are mast-cells, lymphocyte T cells, eosinophils and 
conjunctival epithelial cells. Once activated through 
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antigen presentation or via pro-inflammatory stimuli, 
they release different preformed mediators and cytokines 
activating a predominantly Th1 cell response (i.e. IL-2, 
IFNγ IL-12 and IL-8). A Th2 response is also present 
in these patients, but to a lesser degree. Furthermore, 
a peculiar feature of AKC is the increased susceptibil-
ity to infection resulting from the compromised innate 
immunity as demonstrated by patients’ deficiencies in 
keratinocyte-derived antimicrobial peptides and in both 
sweat and tears IgA. This results in eye infections with 
Staphylococcus aureus, as well as Herpes simplex virus.
The symptoms of AKC are characterized by itching, 
watering and a stringy mucoid discharge. Patients with 
AKC may have prolonged exacerbations of disease that 
are difficult to control and which are associated with red-
ness, severe photophobia, extreme discomfort/pain and 
blurring of vision. The disease is bilateral and symmetri-
cal. The tarsal and fornix conjunctiva are affected in all 
forms of the disease and are chronically inflamed. Papil-
lary hypertrophy of both the upper and lower tarsal con-
junctiva is common in the early years of the disease and 
giant upper tarsal papillae may occur in some patients. 
The conjunctiva is often so thickened by infiltrate that 
the tarsal vessels are obscured. Later in the course of the 
disease the papillae may be largely replaced by sheet scar-
ring. Trantas dots may occur transiently at the limbus, 
and on the tarsal conjunctiva, during exacerbations of 
the disease and are usually associated with limbal swell-
ing. Severe inflammation results in punctate corneal ero-
sions and filamentary keratitis, which can progress to 
frank corneal erosions and a shield ulcer with a mucous 
plaque within 24  h. Plaques may result in corneal thin-
ning, vascularization and perforation. Patients often have 
severe eczema of the eyelids and increased pigmentation 
of periorbital skin (panda eyes). There may be, at last, an 
associated atopic blepharoconjunctivitis.
The clinical features together with a personal or family 
history of atopic dermatitis are usually sufficient for the 
diagnosis. Laboratory investigations are needed where 
the diagnosis is uncertain. Diagnostic dilemmas may 
occur in patients who do not respond to topical therapy 
and in the presence of conjunctival scarring to differen-
tiate AKC from other causes of conjunctival scarring 
associated with chronic conjunctivitis such as primary 
Sjogren’s syndrome, ocular rosacea, ocular mucous mem-
brane pemphigoid and surface neoplasia. Relevant oph-
thalmic investigations include: ocular cytology, upper 
tarsal conjunctival punch biopsy and tear IgE assessment. 
Confocal microscopy may represent an additional tool 
for helping to refine the diagnosis when uncertain. Spe-
cific serum IgE and skin prick tests have poor value in the 
diagnosis.
The management of AKC is often a therapeutic chal-
lenge because of the chronicity of the disease punctuated 
by exacerbations of keratoconjunctivitis and complicated, 
especially in the elderly, by secondary infectious and 
herpetic keratitis, glaucoma, cataract and keratoconus 
[79]. The goals of treatment are to achieve symptomatic 
control, reduce the frequency and morbidity of corneal 
complications and minimize the side effects. Atopic kera-
toconjunctivitis therapy may be divided into conservative 
measures and higher risk second-line therapeutic agents 
[80]. Conservative measures include cold compresses, 
lubrication with preservative free drops, and the use of 
topical cromones. The addition of topical or oral anti-
histamines may be helpful in relieving the symptom of 
itch in some patients. Patients with more severe disease 
are refractory to these treatments and require the use of 
second-line topical therapeutic agents, starting with pro-
longed courses of topical or oral steroids to control the 
inflammation. The disadvantage of these agents is that 
they often achieve symptomatic and inflammatory con-
trol, but at the expense of steroid side-effects including 
raised intraocular pressure, cataracts, arterial hyperten-
sion and osteoporosis. The addition of immunosuppres-
sive agents such as cyclosporin A and tacrolimus has 
been described in the treatment of AKC. Although these 
agents are effective and may be useful as steroid-sparing 
agents, they need to be prescribed carefully in view of 
an increased risk of local and systemic infections, par-
ticularly in aged people whose immune response may be 
already impaired. The use of newer biological therapies is 
currently being explored [81]. Agents such as infliximab 
(anti-TNFα), alefacept (T-cell inhibition), and rituximab 
(anti-CD-20) have proven to be effective in the treatment 
of atopic dermatitis and may have a role in patients with 
AKC unresponsive to conventional systemic immuno-
suppressive therapy. Topical or systemic antibiotics are, 
at last, useful for managing ulcerative blepharitis.
Allergic asthma in the elderly
Asthma in the older adults has become a hot topic in 
respiratory medicine because it poses intriguing ques-
tions in terms of pathophysiological mechanisms, and 
challenges the traditional diagnostic approach and thera-
peutic algorithm that are commonly applied to younger 
populations. One of the main complicating factors lies in 
the fact that the respiratory system is particularly suscep-
tible to time-related deterioration in structure and func-
tion [82], approaching a condition that is often confused 
with that of chronic obstructive bronchitis or emphy-
sema. The prevalence of asthma in older populations is 
not different from that of younger age groups; however, 
geriatric asthma presents with clinical and functional fea-
tures that make its management a potential complex and 
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complicated task; among them, the atopic condition, or 
more precisely, the lack of it. The question is not whether 
asthma in the elderly is a rare disease, but rather whether 
allergic asthma is a rare entity in the elderly. The immune 
system undergoes an involution process with increasing 
age; as a consequence the immunoglobulin production, 
including IgE, declines leading to the misconception that 
asthma in the elderly has a non-allergic pathogenesis. The 
clinical implications of this phenomenon are that atopy 
is relegated to a corner in the assessment of the geriat-
ric respiratory patient. This has greatly contributed to 
underdiagnosis and misdiagnosis of asthma in the most 
advanced ages.
Atopy refers to the predisposition to develop allergic 
diseases, such as allergic asthma, and describes the ability 
to mount IgE responses to common allergens. The initial 
observations on general population samples of a reduc-
tion of atopy with age reinforced the theory that aller-
gic asthma is a rare nosologic entity in the elderly. With 
the aim of providing a definite answer to this doubts, 
Scichilone and colleagues [83] conducted a systematic 
revision of published articles on the topic, and found that, 
overall, the prevalence of allergic sensitization is lower in 
the most advanced ages. These findings were confirmed 
by a survey conducted on large European population [84], 
which showed that positive skin prick test for all allergens 
tended to be less common in older adults than in younger 
ones. It must be stated, however, that the published litera-
ture in the field suffers from the lack of longitudinal stud-
ies to confirm the reduction in the atopic condition with 
ages. In other words, a lower prevalence of atopy in the 
elderly as demonstrated by cross-sectional observational 
studies could simply reflect a lower prevalence of atopy in 
the same individuals at younger ages. Another factor to be 
kept in mind is that, when defining atopy, increased total 
IgE levels and positive skin prick test to allergens are used 
interchangeably, whilst the use of specific IgE towards 
aeroallergens could be more appropriate. A distinction 
should be made between asthma occurring for the first 
time in older ages (late-onset asthma), and asthma that 
begins in younger ages (early onset asthma). The former is 
historically believed to have a lower likelihood of allergic 
features [85]. The assessment of the features of late onset 
asthma is complicated by the fact that some investigations 
included as “late” asthma cases presented in adulthood. 
In addition, the so-called “recall bias” could have affected 
the definition of asthma in the elderly as late-onset rather 
than long standing.
Persistent antigen exposure characterizes the natural 
course of allergy: the continuous stimulation with the 
same antigenic proteins leads to the expression of new 
surface molecules together with the expansion of effec-
tor and memory cells. This translates into a decrease in 
the number of naive cells and an increase in the number 
of sensitized cells. Therefore, in allergic asthma the naive 
T cells tend to decrease whereas the T lymphocytes are 
constantly stimulated by the aeroallergens. Of note, age 
also affects mast cell and basophil mediator releaser and 
the responsiveness of other inflammatory cells to the 
chemoattractive and activating signals of mast cell and 
basophil mediators, which influence the inflammatory 
cascade that follows the IgE receptor bridging.
The haematopoietic compartment of bone marrow 
is replaced by fatty adipose tissue with increasing age 
[86], with a functional decline in stem cell precursors 
which, however, seems to occur only under stressing 
conditions; in basal conditions the absolute numbers of 
eosinophils and basophils in young versus older subjects 
does not differ [87]. An old investigation carried out in 
elderly subjects showed that paracortical and medullary 
zones of lymph nodes were strongly reduced, with lower 
germinal centres [88]. Furthermore, aging is associated 
with changes in the function of lymphocytes, such as a 
lower antibody response, a decreased ability to produce 
high affinity antibodies and reduced IgG isotype class 
switching [89]. Increasing age is also associated with an 
attenuation of dendritic cell function. Agrawal et al. [90] 
reported that peripheral blood dendritic cells are similar 
in young and aged subjects, but migration and phagocy-
tosis are impaired in older adults. Aging is characterized 
by macrophage dysfunctions consisting in the reduction 
of expression of TLRs, secretion of cytokines following 
activation, and phagocytic ability [91].
Scichilone and colleagues [83] point out that, despite 
lower prevalence of atopy in the elderly, the prevalence 
of the allergic component remains high in older indi-
viduals suffering from asthma, and this may have clinical 
consequences. For example, the age-related reduction in 
the production of IgE does not decrease the efficacy of 
a pharmacological approach with anti-IgE in the severe 
forms of asthma occuring in older ages. Although less 
frequent, the allergic reactions in older adults can be 
even worse than in younger people, because of the inabil-
ity of other organs and systems to compensate. For exam-
ple, a systemic anaphylactic reaction may have dramatic 
consequences in elderly subjects in whom the cardio-
vascular system is not able to effectively compensate. In 
addition, atopy can interact with other conditions (pri-
marily viral infections), eliciting more severe exacerba-
tions in the elderly. Regardless of age, the assessment of 
atopy is crucial in the comprehensive evaluation of the 
chronic respiratory patient, in that, it provides the unique 
opportunity to act on the environment (removal of aller-
gens) and to modify the natural history of the allergic 
condition with allergen immunotherapy. Indeed, age per 
se does not preclude the use of allergen desensitisation.
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The relationship between the presence of the allergic 
component and the geriatric age may be complicated 
by the incorrect interpretation of skin testing. This may 
be due to the age-associated reduction in skin reactiv-
ity of the elderly to histamine and allergens. In addition, 
the area of the skin where the test is performed could be 
atrophic with decreased cellularity, thus influencing the 
response to allergens. The reduction in blood vessels and 
mast cells reduces the binding sites for allergen and the 
release of histamine to produce wheal and flare. Finally, 
mast cells function can be impaired by prolonged expo-
sure to sun, as often occurs in the elderly. A negative skin 
prick test does not rule out completely the presence of 
an allergic condition. The concept of localized mucosal 
allergy with the production of specific IgE antibodies in 
the absence of atopy has been put forward, and is cur-
rently an object of investigation. Taken together, these 
observations allow to speculate that the immunological 
and inflammatory responses to stimuli may be different 
in the older ages, implying a different history of the dis-
ease. It is logical then to hypothesize that asthma in the 
elderly will have to be treated accordingly.
Allergen immunotherapy in the elderly
General aspects of AIT
Allergen (specific) immunotherapy (AIT) was introduced 
in clinical practice more than one century ago, with the 
supposed aim of “vaccinating” against hypothetical “aero-
genic toxins”. Despite the rationale was wrong, the proce-
dure resulted to be clinically effective and rapidly spread. 
Subcutaneous injections (SCIT) remained the only mode 
of administration for more than 70  years, when new 
modalities were proposed, with the aim of improving the 
safety and convenience. Among the various routes pro-
posed, the sublingual one (SLIT) rapidly gained credibil-
ity, so that it was accepted as a viable alternative to SCIT 
in all official documents and guidelines [92]. In general, 
the clinical efficacy of SLIT and SCIT are equivalent, 
although SLIT has a more favourable safety profile [93].
To date, the practice of SCIT is sufficiently stand-
ardized, as testified by position papers and practice 
parameters [94–97]. On the other hand, SLIT can be 
administered as drops, monodose vials or tablets, with 
variable timings and doses depending on the manufac-
turer. In the last decade, highly standardized products 
in tablets (grass, mite, ragweed) have been approved as 
drugs by EMA and FDA. The aim of AIT is of interfering 
with the immune response to the offending allergen, thus 
inducing a tolerance that results in a reduction of symp-
toms and medication intake upon natural exposure to 
the allergen itself. SCIT usually consists of an updosing 
phase (with gradually increasing doses of the allergen) 
followed by a maintenance phase, were the maximum 
dose is given at regular intervals (usually monthly) for 
3–5 years. With SLIT, due to the favorable safety profile, 
the updosing phase is absent or very short, and the main-
tenance is given on daily basis.
Mechanisms of AIT
Differently from traditional medications, AIT is not a 
mediator or receptor inhibitor but rather a biological 
response modifier. Its mechanisms of action are mul-
tiple and complex, and exerted at various levels of the 
allergen-induced inflammatory reaction. The complexity 
of the immune-mediated actions of AIT have been exten-
sively described in many reviews [98–100].
Briefly, the sensitizing molecules contained in the aller-
gen extract (independent of the mode of administration) 
are recognized by antigen presenting cells, processed and 
presented to Th lymphocytes. This results in the activa-
tion of T regulatory (Treg) cells which, through the pro-
duction of numerous cytokines (IFN-γ, IL-10, IL-12) 
induce:
  • A relative shift from the Th2 towards the Th1 phe-
notype (allergic subjects have an imbalance in the 
Th2/Th1 lymphocyte in favour of Th2). This reduces 
the production of IL-5, IL-4, IL-13 that specifically 
favour the allergic inflammation.
  • A decrease in allergen-specific IgE synthesis.
  • An increased production of allergen-specific IgG4, 
which block the IgE-facilitated antigen presentation.
All these modification are not permanent, but they are 
long-lasting, as testified by the fact that the clinical ben-
efit obtained in a successful course of AIT may persist 
for years after discontinuation. In addition, the disease-
modifying effect can affect the natural history of allergic 
diseases (for instance reducing the risk of asthma onset) 
[101].
The “problem” of AIT in the elderly
As a matter of fact, the use of AIT in elderly people has 
been until the last decade a neglected aspect. Looking at 
the available literature, and particularly at randomized 
trials, it appears that patients aged 65 years or older are 
never included in the study population [94–96]. Guide-
lines are usually elusive. Some of them indicate older ages 
as a relative contraindication to AIT [102], some others 
do not mention this aspect [97], and in others caution 
is recommended, especially concerning the problem of 
safety and the treatment of severe reactions [103]. This 
fact is the consequence of two consolidate beliefs. First, 
allergic diseases are expected to be relatively rare in aged 
patients and, second, it is thought that with ageing the 
immune system loses its ability to efficiently respond 
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with specific IgE. On this background, AIT has never 
been considered a therapeutic option for older people. 
The context is further complicated by the frequent pres-
ence of comorbidities, and consequent poly-pharmaco-
therapy, that can interfere with AIT (e.g. ACE inhibitors, 
betablockers or major antidepressants).
Indeed, in the recent years it has become clear that the 
allergic respiratory diseases are not a rare situation in 
elderly people [104]. In fact, the prevalence of respiratory 
allergy (asthma and/or rhinitis) have been shown to range 
between 5 and 10% in various studies [105, 106]. Lom-
bardi et al. [107] have recently shown that the prevalence 
of allergic sensitizations with clinical manifestations in 
older subjects approximates 50%. In another cross-sec-
tional study, involving about 2000 elderly patients with 
a clinical suspicion of allergy, the prevalence of asthma, 
seasonal rhinitis and perennial rhinitis were found to be 
5, 13 and 17%, respectively [108]. Thus, despite the prob-
lem is considered of scarce relevance, the available data 
testify for a not negligible social impact. Concerning the 
immune system, the phenomenon of “immune-senes-
cence” is well known since many years. It is characterized 
by an overall reduction in: bone marrow proliferation, 
antigen-presenting function, capacity of mounting an 
antigen-specific humoral response [89, 109, 110]. This 
would result in a decreased capacity of synthesizing IgE. 
It is true that in several studies, the acquired immunity 
seem to decline with age [for review see 84]. On the other 
hand, several studies have demonstrated that the Th2-
driven response in the elderly does not differ from that 
of younger subjects [111, 112] and that the production of 
IgE does not always decline [113]. In addition, the nasal 
cytology aspect in elderly subjects with allergic rhinitis is 
identical to that of young patients [114], and a local nasal 
specific IgE response is detectable also in aged patients 
[115].
The evidence
Due to the above mentioned limits, it is easy to under-
stand that there are very few clinical trials exploring the 
effects of AIT in elderly subjects. In a nonrandomized 
open controlled study of SCIT for birch and ragweed 
allergy involving a total of more than 100 patients, the 
clinical benefit was identical in patients aged less or more 
than 55  years, and greater than in controls not receiv-
ing SCIT [116]. Subsequently, other Authors [117] per-
formed a retrospective study where the effects of SLIT 
(symptom/medication scores, bronchial hyperreactiv-
ity, pulmonary function) were compared between young 
adults (18–55  years, n  =  49) and older patients (55–
65 years, n = 40). They found no difference between the 
two age groups in the magnitude of the achieved clini-
cal efficacy. More recently, Bozek et  al. [118] explored 
the effects of SLIT in 108 patients aged 60–75 years and 
receiving dust mite SLIT or placebo for 3  years. Main 
findings were that total nasal scores decreased by 44% 
VS baseline in the SLIT and by 6% in the placebo group 
and medication score decreased vs baseline 35% in 
SLIT group, although no change was observed between 
groups at the specific nasal challenge. The same Authors 
assessed the efficacy of pre-seasonal grass pollen AIT in 
subjects aged 65  years or more and suffering from sea-
sonal rhinitis [119]. Sixty patients were randomized to 
receive AIT or placebo for 3  years, and the area under 
the curve for symptoms + medications score was evalu-
ated at the 3rd year. The reduction of this parameter ver-
sus baseline was significantly greater in the active group, 
and the symptom score, medication score and combined 
decreased by 50% on average.
Polytherapy may represent a problem in selected cases 
and with selected drugs that in principle can interfere 
with the course and treatment of severe reaction if any 
occur. For instance, beta blockers may counteract and 
monoamine oxidase inhibitors may potentiate the effects 
of epinephrine, when it is given for anaphylactic reac-
tions (one of the possible although rare side effects of 
AIT). Indeed, the new selective betablockers do not carry 
this risk, and in fact have been indicated only as relative 
contraindication in the more recent literature reviews, 
whereas monoamine oxidase inhibitors do not repre-
sent a contraindication. The same holds true for ACE 
inhibitors, for which the risk of worsening hypotension 
in anaphylaxis has not been substantiated [97, 120]. Car-
diovascular diseases are not per se a contraindication to 
AIT as well. Venom AIT represent a special case, since 
the risk of anaphylaxis after sting in sensitized subjects 
(especially the elderly) is always greater than any possible 
risk due to cardiovascular diseases or drugs interfering 
with epinephrine.
In conclusion, there is increasing evidence that aller-
gic disorders in the elderly are not rare, and an efficient 
IgE response can be expected also in this age group. On 
the other hand, the few evidence so far available for AIT, 
consistently confirm that the treatment is effective also 
in older subjects. Thus, provided that the IgE-mediated 
nature of the disease is clearly ascertained and that the 
offending allergen is unequivocally identified, AIT can be 
prescribed also in the elderly, with the same indications 
and modalities applied in young adults. In the elderly, 
additional care should be paid in assessing the pres-
ence of comorbidities, the use of multiple drugs, and the 
expected compliance.
Chronic urticaria in the elderly
As all organs, the skin ages with structural and functional 
consequences that may lead to clinical conditions. The 
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“skin aging” hallmarks are: (1) atrophy of the epidermis 
and dermis due to loss of hydration; (2) progressive loss 
of function and structural integrity resulting in impaired 
immune response and skin barrier function; (3) skin 
vascular impairment; (4) metabolic imbalance of reac-
tive oxygen species, and components of the extracellular 
matrix [121]. Aged skin is characterized by atrophy, wrin-
kling, fragility, alterations in pigmentation, a higher fre-
quency of benign and malignant tumours, and a greater 
tendency to xerosis [122]. These factors contribute to 
greater susceptibility to dermatologic diseases in individ-
uals over the age of 65 years. In this context, one of the 
most common skin diseases is the allergic contact derma-
titis (ACD), which is mainly due to the direct exposition 
to nickel sulphate (11–12%) and fragrance/balsam of Peru 
(7–9%). Atopic dermatitis (AD) is much less common in 
the elderly in comparison with children and young adults. 
AD is associated with seasonal mucosal allergies, asthma 
and positive prick tests to various allergens [123]. Late 
onset AD, without the usual history of atopy, may explain 
eczema of unknown origin and negative patch tests. Sca-
bies should enter the differential diagnosis in generalized 
dermatitis, as institutional acquisition of scabies is com-
mon in the elderly.
Chronic urticaria (CU) is a common nosological entity 
in older individuals. This is especially true for the spon-
taneous form of the disease, although there are few data 
regarding epidemiology and clinical features. Urticaria is 
defined as itchy wheals with or without angioedema that 
usually persists for less than 24 h. According to current 
EAACI/GA2LEN/EDF/WAO guidelines, CU can be clas-
sified as spontaneous, physical, or other [124]. Chronic 
spontaneous urticaria (CSU) is the most common sub-
type of all forms of non-acute urticaria, and is charac-
terized by wheals that develop independently of external 
stimuli and last for a minimum of 6 weeks. In general, the 
underlying causes of CSU are difficult to identify in most 
patients. It is estimated that about 0.5–1% of the popula-
tion suffers from CSU, and that about one quarter of the 
population has experienced urticaria at some point dur-
ing their lives. Both sexes can be affected, but in general, 
females appear to suffer from urticaria nearly twice as 
frequently as males.
The pathogenic mechanisms of CSU are unclear. Evi-
dence of an autoimmune etiology is reported in about 
45% of CSU patients, remaining unknown in the remain-
ing subjects. Circulating autoantibodies specific to high-
affinity immunoglobulin E (IgE) receptors or dermal mast 
cell bound IgE activate mast cells and induce degranula-
tion with cytokine release [125]. The autologous serum 
skin test (ASST) is a screening test for autoreactivity; if 
positive, it suggests the presence of circulating histamine-
releasing factors of any type, and not only of functional 
autoantibodies. Atopy is proposed to play some role in 
the pathogenesis of CSU, especially in the aspirin-intol-
erant CU phenotype. Several hypotheses exist regarding 
the relationship of atopy and aspirin intolerance; how-
ever, the exact association remains unclear.
Systemic diseases that may induce elderly urticaria 
should be carefully evaluated. Findings derived from the 
Mayo Clinic’s electronic database revealed that patients 
presenting a new diagnosis of CU at older ages were 
more likely to have underlying monoclonal gammopa-
thy of undetermined significance (MGUS). Some authors 
have also emphasized the role of drug-induced urticaria 
in the geriatric population [126].
Angioedema in the absence of urticaria can be due to 
overproduction of bradykinin [127]. It is exceptional 
that hereditary deficiency in the C1 inhibitor (HAE-C1-
INH) has its onset in the elderly. It is more frequent that 
acquired C1 inhibitor deficiency (AAE-C1-INH) pre-
sents in the older age, and it is characterized by activa-
tion of the classical complement pathway and accelerated 
catabolism of C1-INH due to lymphatic tissue neoplasms 
or autoimmune diseases. The prevalence of angiotensin-
converting enzyme inhibitor angioedema (AE-ACEi) is 
relatively high, ranging 0.1–2.2%, and it should be sus-
pected in all patients with AE who are receiving ACEi. 
Normal levels of complement factors help to reinforce 
the clinical suspicion and to rule out the possibility of AE 
with C1-INH deficiency.
In a retrospective investigation conducted on a large 
cohort of patients with CU from the National Health 
Insurance Research Database of Taiwan, Chen and col-
leagues found that a quarter was in the age range of 
60–79  years and 3.4% were 80  years and older [128]. A 
study performed by Magen and collaborators on 1598 
adults suffering from CSU found that 9.4% were elderly 
[129]. Interestingly, the latter showed lower rates of angi-
oedema and dermographism, as well as fewer wheals 
and ASST positivity. At variance with the younger pop-
ulations, no sex differences were demonstrated in the 
elderly, whereas comorbid conditions, such as diabetes 
mellitus, chronic renal failure, hypertension, Hashimoto’s 
thyroiditis, and malignancies were more prevalent in the 
elderly [129].
Ventura et  al. [130] found that CSU due to infections 
was more common in the elderly, especially the CSU 
forms related to Helicobacter pylori and those related to 
the sensitization to the parasitic nematode Anisakis sim-
plex. Ban et al. [131] reported that in the elderly with CU 
there is a high prevalence of AD compared with younger 
groups. The prevalence of AD was equal to 37.8 versus 
21.7%, respectively (p  =  0.022). Disorders of the skin 
barrier are found in subjects suffering from AD and this 
leads to the colonization of Staphylococcus aureus, the 
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degraded ceramide of which penetrates the skin barrier 
and induces IgE sensitization.
Elderly CSU diagnosis
As a general concept, the diagnostic approach to CSU is 
not influenced by age. Indeed, the international guide-
lines do not recommend a specific work-out for elderly 
populations, although a careful assessment of the drug 
history should be encouraged (especially for aspirin and 
ACE inhibitors), and the presence of autoimmune or 
neoplastic diseases ruled out [132]. An extended labora-
tory and instrumental tests should be reserved to specific 
conditions as judged by the physician.
Elderly CSU treatment
The avoidance of causal and/or triggering factors is the 
first choice in the management of CSU. This is however 
a rather complicated task, given that in the majority of 
cases the recognition of these factors is unsuccessful. 
The pharmacological treatment of CSU raises a safety 
issues mainly due to concomitant diseases and polyphar-
macotherapy, which are common in older subjects and 
may cause drug-to-disease and drug-to-drug interac-
tions. Indeed, the potential for drug interaction increases 
with age and with the number of drugs prescribed [133]. 
According to the international guidelines, the manage-
ment of CSU is based on a step-wise approach, with 
sequential steps to be implemented according to the 
clinical response. The mainstay treatment for CSU in 
the elderly consists of new-generation non-sedating 
antihistamines. First generation H1 receptor antago-
nists are lipophilic and therefore may cross the blood–
brain barrier. For this reason, elderly individuals may be 
at increased risk of adverse effects involving the CNS 
(confusion, sedation, dizziness, sleepiness, and impaired 
cognitive function). Agostini et  al. [134] showed that 
the administration of diphenhydramine in elderly hos-
pitalized patients was associated with increased risk of 
cognitive decline compared with non-exposed patients. 
Because of the lack of specificity for the H1 receptor, due 
to activation of dopaminergic, serotoninergic, muscarinic 
and cholinergic receptors, the first-generation antihista-
mines have also additional adverse effects with an higher 
risk of urinary retention, constipation, as well as arrhyth-
mias, peripheral vasodilatation, and postural hypoten-
sion. First-generation antihistamines should therefore 
be prescribed with extreme caution in elderly patients. 
Second-generation oral H1 anti-histamines have a safety 
profile with reduced capacity to induce CNS-related 
adverse effects as they have a low potential to cross the 
blood–brain barrier, and provide selective H1 receptor 
blockade without anticholinergic activity. It is instead 
important to remember that second-generation oral H1 
antihistamines potentially requiring a dose reduction 
in patients with hepatic diseases or dysfunction include 
cetirizine, ebastine, levocetirizine, and loratadine. Those 
potentially requiring a dose reduction in patients with 
renal dysfunction include cetirizine, ebastine, fexofena-
dine and levocetirizine. Conversely, no dosage adjust-
ment for desloratadine is required in the elderly healthy 
subjects [135]. Pharmacokinetic/pharmacodynamic stud-
ies in special populations indicate that bilastine’s dose 
adjustment is not necessary in elderly patients, or in 
hepatic or renal insufficiency [136]. The safety of second-
generation oral H1 receptor antagonists up-dosing has 
not been systematically evaluated in the older population.
With regard to the third-line therapy for CSU, very few 
studies explored the effect of montelukast in the elderly. 
Available data reassure on the safety profile of montelu-
kast in the elderly patients, and dose adjustments are not 
necessary even in individuals affected by renal or hepatic 
failure. It must be stated, however, that montelukast 
can interact with drugs that interfer with the CYP3A4, 
CYP2C8, or CYP2C9 systems.
Alternative treatment options have not been systemati-
cally evaluated in elderly patients with CSU. Corticoster-
oids and cyclosporine could be used with caution in cases 
resistant to therapy. Old age may be a risk factor for par-
ticular corticosteroid-associated side effects and adverse 
reactions (diabetes, cataract, and osteoporosis).
The anti-IgE humanized monoclonal antibody (omali-
zumab) has been successfully tested in subjects with CSU 
up to 75 years of age, namely 4–9% in the study of Maurer 
and colleagues [137], and 3.7–5.2% in that of Saini and col-
leagues [138]. Kaplan and coauthors showed that anti-IgE 
treatment was effective irrespective of age [139]. No omali-
zumab dose adjustment is recommended for elderly patients 
or those with impaired renal or hepatic function, and there is 
no evidence of clinically significant drug interactions [140]. 
The literature contains sporadic reports of older patients 
with difficult-to-treat CSU and/or chronic inducible urti-
caria treated with omalizumab; in one case the highest age 
was 82  years. Nowadays, specific data are not available on 
omalizumab treatment in elderly patients with CSU.
In conclusion, CSU in the elderly induce severe dis-
ability and decrease in quality of life and CSU can be 
associated with other diseases (autoimmune, infectious, 
neoplastic, etc.). Polypharmacological treatment is very 
frequent in the elderly patients, and should be taken 
into account in the treatment of CSU, as it can induce 
drug interaction due to the various comorbidities and 
changes in pharmacokinetics and pharmacodynamics. 
Like adults and children, the mainstay treatment for CSU 
in the elderly consists of new-generation non-sedating 
antihistamines.
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Food allergy in the elderly
The incidence of IgE-mediated allergic reactions is rising 
worldwide. The changes of the demographic parameters 
let foresee such a meaningful increase in the propor-
tion of allergic patients in the next few years, so that 
the possibility of missed recognition or under diagnosis 
should be avoided [141]. In particular, a recent paper on 
food allergy carried out in a geriatric nursing home on 
subjects with a mean age of 77  years showed that 40% 
of the patients had specific IgE to respiratory allergens 
and 24.8% to food allergens, with a direct correlation to 
the positivity of skin prick tests (SPT). According to the 
authors the problem of food allergy (FA) in the elderly 
is underestimated, because epidemiological studies are 
focused mainly on children and on adults, as if the elderly 
could not be affected by these allergies [142].
An incidence of 5% FA in people over 65 was diagnosed 
in outpatients of the Allergy Section at Hospital Vall 
d’Hebron, in comparison to the 36% diagnosed in people 
aged between 40 and 65 and to the 6 9% in the young-
est [75]. The profile-sensitization was not much different 
among the groups, except for the Rosaceae fruits and fish, 
which were found to be much more frequent in younger 
people [75]. In addition, data from the literature show 
that with regard to the clinical manifestations anaphy-
laxis from food allergens is less frequent in the elderly in 
comparison with young subjects [143]. Another recent 
work has shown that in a geriatric Immunoallergology 
Unit one-third of the patients over 65 who were afferent 
to the structure and had been visited and subjected to 
specific allergy tests for suspected food allergy were posi-
tive to SPT to food; it confirmed the diagnosis of FA [76].
To understand the reasons of FA occurrence in the 
elderly it is appropriate to reevaluate the physiological 
changes that occur in the mucosal immune system. In 
fact it should not be forgotten that the gastrointestinal 
tract is the largest immunologic system with an impor-
tant number of lymphocytes; part of them are isolated 
and part of them are aggregated in lymphatic structures 
called Peyer’s patches. In addition, this system plays a key 
role in all reactions involving mucosal immunity, includ-
ing FA. It takes particular importance in the elderly due 
to the physiological involution of the thymic gland and its 
related functions [144].
As a matter of fact it is in the intestinal mucosa and in 
the immune related tissue, the so called gut associated 
lymphoid tissue, that occur the modifications which are 
responsible for the change in the oral tolerance. Gener-
ally the oral tolerance that is established at a young age 
is maintained even over 65, unless new antigens which 
are unknown to the immune system [145] are intro-
duced. As a consequence, the induction of tolerance to 
new antigens is reduced in elderly mice. These data show 
clearly that the answers of the Secretory Antigen-specific 
IgA (S-IgA) and oral tolerance is modified in aged mice; 
even with regard to the protection from infectious dis-
eases, some alterations that should be better investigated 
can occur especially in humans [146]. Another impor-
tant factor responsible for changes in oral tolerance is 
the alterations of the gastrointestinal permeability. The 
intestinal barrier integrity interruptions may arise after 
the appearance of alterations in the gastroenteric mucosa 
[147]. They occur mainly at the level of tight junction 
(Tj) for alterations of both canonical and non-canonical 
activation of NK-κB pathways in intestinal epithelial cells 
[148]. These structures, that generally provide a “barrier” 
effect, become more permeable both for the alteration of 
mucosal epithelium due to inflammatory diseases of the 
gastrointestinal tract and for the effect of some cytokines 
whose secretion is increased in the elderly, such as IL-6, 
TNFα and IL-β, responsible for a “pro-inflammatory” 
status, the so called “inflamm-aging” [13, 149]. In par-
ticular the epithelial cells, which are responsible for the 
production of large amounts of cytokines, including the 
IL-β, increase the permeability of the mucous mem-
brane through the reduction of the proteins of the Tj and 
occludens zonula [150]. This weakening of the “barrier 
effect” results in a modification of the mechanisms of oral 
tolerance and thus predisposes to FA. Another key fac-
tor is the presence of inflammatory cytokines at this level. 
A recent study confirmed it proving that in the biopsies 
of the intestinal mucosa of old baboons there is an up-
regulation of micro RNA, miR-29a and of inflammatory 
cytokines IFN-γ, IL-6 and IL-1β[1511]. The role of S-IgA 
should not be forgotten too. These immunoglobulins play 
a critical function both for the maintenance of the intes-
tinal microbiota and consequently for the modulation of 
local immune responses [151].
With regard to the IgA there are conflicting stud-
ies about the maintenance of an optimal level of IgA in 
the gastroenteric tract in the elderly. Although the IgA 
reduced levels can rather reflect an alteration of the 
migration of plasma cells secreting IgA from effector to 
inductor sites, rather than their actual numerical reduc-
tion [152]. However it is reported that Antigen-specific 
responses of IgA type are weaker in elderly animals. In 
addition, young mice have less somatic mutations of IgA 
if compared to older mice, and the analysis of more than 
a million VH sequences showed that the IgA repertoire of 
the young differs from that of the elderly [153]. It is not 
yet fully clarified how these differences can result in the 
decreased efficacy of the security role exerted by the IgA 
in humans.
Moreover, the habit of eating raw fish, common in Italy 
and in other countries, is connected to the possibility 
of developing allergic sensitization to Anisakis simplex, 
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whose incidence increases over the years because of the 
increase of exposure [154]. This sensitization is expressed 
with typical clinical manifestations of FA including 
especially hives, but also more severe reactions such as 
asthma and anaphylactic shock [155]. In particular it has 
been shown that even in this case a situation of impaired 
gastric permeability, which can promote massive pen-
etration of allergens and induce important clinical mani-
festations, can also coexist [156].
According to Diesner et al. [142] during senescence the 
changes that occur in the innate immune system, as well 
as in adaptive, justify the appearance of FA. At the same 
time the lack of some micronutrients, including zinc 
and iron or vitamin D may be a risk factor. In particular 
the reduced level of zinc, frequent in elderly subjects, is 
responsible for the reduction of Th1 cytokines, while it 
does not interfere with the production of Th2 cytokines, 
that promote the increase of allergic diseases in the 
elderly [157]. The reduction of iron, which occurs often 
in the elderly, is another risk factor. In fact, it is respon-
sible for a diminished antibody response, especially with 
regard to the IgG4 subclass that can prevent activation of 
effector cells through the capture of allergens before they 
can act the IgE-mediated binding [158].
Even vitamin D could play a role through T cells and 
antigen presenting cells by promoting tolerance via inhi-
bition of inflammatory responses and the induction of 
regulatory T cells [159]. Another contributing factor 
is represented by atrophic gastritis, which is a frequent 
disease among the elderly, or from the excessive use of 
alcohol, proton pump inhibitors or antacids. As a conse-
quence undigested proteins that take on allergenic prop-
erties would remain in the stomach triggering FA [160].
In conclusion, FA represents an emerging problem in 
the elderly, complicated by gastrointestinal mucosa per-
meability and impaired function of the local immune 
system.
Drug allergy in the elderly
We define “adverse drug reactions” (ADRs) any untoward 
reactions to a medication. ADRs may be broadly divided 
into two types: A (reactions occurring in most normal 
patients, given sufficient dose and duration of therapy: 
common and predictable) and B (drug hypersensitivity 
reactions restricted to a small subset of the general popu-
lation: rare and unpredictable). A drug allergy (DA), i.e. 
an allergic drug reaction, is an adverse drug reaction that 
results from a specific immunologic response to a medi-
cation, therefore a Type B reaction (10–15% of ADRs). 
It is a reaction which cannot be usually predicted and 
occurs in a susceptible kind of patients. There are excep-
tions: predictable hypersensitivity reactions to abacavir, 
dapsone, carbamazepine, allopurinol end flucloxacillina 
in patients with certain leucocyte antigen (HLA). Signs 
and symptoms are different from the pharmacologic 
actions or the collateral effects of the drug. DA account 
for about 6–10% of all ADRs, but for up to 10% of the 
fatal reactions [161]. The term “immunologic drug reac-
tion” is also used to describe these reactions. Immuno-
logic drug reactions can be mediated either by humoral 
immunity (IgE, IgG), or by lymphocytes. There are dif-
ferent systems for classifying DA. One is based upon 
the immunologic mechanism and identifies four catego-
ries (Gell and Coombs): Type I, immediate in onset and 
mediated by IgE and mast cells and/or basophils, Type II, 
delayed in onset and caused by antibody (usually IgG)-
mediated cell destruction, Type III, delayed in onset and 
caused by IgG-drug immune complex deposition and 
complement activation and Type IV, delayed in onset 
and T-cell mediated (Type IV reactions may be further 
subdivided into IVa, IVb, IVc, and IVd). Types I and IV 
reactions are far more common than types II and III, the 
latter usually following prolonged, higher dose therapy. 
Most medications cause just one type, although certain 
drugs, such as penicillin, or glucocorticoids can induce 
all types [162]. A second classification is based upon the 
timing of symptom onset. The WAO has recommended 
that, based upon the timing of the appearance of symp-
toms, immunologic drug reactions be divided into imme-
diate reactions (onset within 1  h after exposure) and 
delayed reactions (onset after 1 h) [163]. However some 
IgE-mediated reactions may appear after 1 h, particularly 
if the drug is assumed per os and especially if together 
with food. Usually, delayed reactions begin after weeks 
of continuous treatment. The reaction, also called “drug-
induced hypersensitivity syndrome” (DiHS), is character-
ized by fever, rash, and multi organ involvement, and may 
or may not be associated with eosinophilia and lympho-
cytosis. It can persist for weeks to months, even after the 
medication is stopped. One such disorder is “drug rash 
with eosinophilia and systemic symptoms” (DRESS), a 
systemic drug reaction that begins 1–12 weeks into con-
tinuous treatment [164]. The liver (hepatitis) and heart 
(hypersensitivity myocarditis) may be affected.
While the prevalence and the risk factors associated 
with the ADRs in the general adult population have 
been well documented, much less is known about the 
ADRs, and in particular about the DAs, in the elderly 
population.
A number of factors in older individuals contribute to 
their increased risk for developing a drug-related prob-
lem. These include female sex, frailty, coexisting medical 
problems, memory issues, and use of multiple, interact-
ing, prescribed and non-prescribed medications [165].
A study of Alhawassi et al. [166] review the Literature 
to estimate the prevalence of the ADRs in the elderly in 
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the acute care setting and to identify the factors associ-
ated with the increased risk in the elderly. The mean 
prevalence of the ADRs in the elderly in the studies 
included in this review was 11.0% (95% confidence inter-
val [CI] 5.1–16.8%). The median prevalence of the ADRs 
leading to hospitalization was 10.0% (95% CI 7.2–12.8%), 
while the prevalence of the ADRs occurring during hos-
pitalization was 11.5% (95% CI 0–27.7%). There was wide 
variation in the overall ADRs prevalence, from 5.8 to 
46.3%. The Authors conclude that the ADRs constitute 
a significant health issue for the elderly in the acute care 
setting. While there was wide variation in the prevalence 
of ADRs in the elderly, according to this study about one 
every ten admissions of elderly patients is due to ADRs 
and 10% elderly patients will suffer from an ADR during 
the hospital stay. Older female patients and those with 
multiple comorbidities and medications appear to be at 
the highest risk of ADR in the acute care setting.
Drug-related hospitalizations account for 2.4–6.5% of 
all medical admissions in the general population; the pro-
portion is much higher for older patients [161, 167]. In 
the United States, it is estimated that annually from 2007 
to 2009 there were 99,628 emergency hospitalizations for 
adverse drug events in individuals aged 65 years or more, 
and two-thirds of these were due to unintentional over-
doses [168]. A meta-analysis found a fourfold increase of 
the rate of hospitalizations related to adverse drug events 
in older adults compared with younger adults (16.6 ver-
sus 4.1%); it was estimated that 88% of the ADR hospi-
talizations among older adults, and 24% among younger 
adults, were preventable [169].
A meta-analysis on UK hospitals found that the fre-
quency of drug-related hospitalizations was between 
2.4 and 6.2% [170] and many of these were considered 
preventable [171]. A recent study in the Netherlands 
[172] that about 41,000 hospital admissions per year 
were related to ADRs and about the half were poten-
tially preventable. The risk was doubled if patients were 
65 or older. The elderly are particularly at risk for drug-
related problems [173]. About 30% of hospital admissions 
of patients aged 65 and over are due to ADRs, most of 
which are preventable [174]. It is also of concern that the 
likelihood of severe long-term outcomes such as disabil-
ity and death following ADRs is significantly higher in the 
elderly population [175]. Epidemiological studies have 
found that the classes of drugs most commonly associ-
ated with ADRs in the elderly include diuretics, warfarin, 
non-steroidal anti-inflammatory drugs (NSAIDs), selec-
tive serotonin reuptake inhibitors, beta-blockers and 
angiotensin converting enzyme (ACE)-inhibitors, chem-
otherapy for cancer, glucocorticoids [176–180].
The data of the Italian Group of Pharmacovigilance 
in the Elderly (GIFA) have shown that age is not an 
independent risk factor but it is associated with signifi-
cant changes in pharmacokinetics and pharmacodynam-
ics that predispose the elderly patients to higher risks. 
Polypharmacy, changes in pharmacokinetics/pharmaco-
dynamics and drug interactions are the main factors pre-
disposing the elederly patients to ADRs [181].
Previous data demonstrates that most of the ADRs in 
the elderly are “preventable”, therefore they are not Type 
B reactions. Ventura et  al. [182] investigated the preva-
lence of unpredictable drug adverse reactions among 
patients admitted to the Emergency Departments (EDs) 
of three large Italian hospitals in the period 2005–2008. 
Clinical characteristics and demographics were carefully 
recorded in a dedicated database. The assessment of the 
drug reactions was carried out by an allergist after the 
first emergency evaluation. Over the considered period, 
56,031 patients were admitted at the ED, 2644 (21.2%) 
of which for ADR. Out of those patients, 55 (2.1%) were 
identified as unpredictable ADRs. In 96% of the cases 
the clinical presentation was cutaneous and antibiot-
ics were the most frequently responsible drugs. Patients 
over 65 years accounted for 37% of the reactions. In those 
patients the multiple drug regimens were significantly 
more frequent, as well as the presence of comorbidities.
In 2007 the Finnish National Agency for Medicines 
made available on its website (http://www.nam.fi/publi-
cations/tabu) the summary of reports received between 
1973 and 2006 about ADRs (including vaccines) in 
patients ≥75  years. Approximately one-third of the 
2013 cases concerned anti-infective drugs. The reactions 
described had the characteristics of type B reactions.
Therefore it can be concluded that: (I) today there are 
no adequate studies that define the epidemiology of DA 
in the elderly and (II) most of the described ADRs are 
not characteristic DAs. By using the evidence from the 
studies it is only possible to estimate that the DAs in the 
elderly have a prevalence of 0.6–2.1% but constitute as 
much as 10% the fatal adverse reactions.
There are three certainties about the DAs in the elderly: 
(a) giving the rising age of the population (a risk condi-
tion) it can be concluded that at the present time is abso-
lutely essential to proceed with adequate epidemiological 
studies; (b) in the elderly the diagnosis must be made 
according to current guidelines [183–185] and there 
should therefore be a “systems” approach, which has a 
historic equivalent in the geriatric “multi-dimensional” 
approach. Evaluation involves a meticulous history of 
past and present ADRs, the acquisition of additional 
information from medical records and an analysis of 
the temporal patterns between drug administration and 
onset of symptoms. Once this data has been assembled, it 
must be combined with our knowledge about the specific 
types of allergic reactions caused by the various classes 
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of drugs, in order to identify the potential culprit agents. 
Advances in drug allergy include identification of HLA 
associations for penicillin allergy and a micro RNA bio-
marker/mechanism for toxic epidermal necrolysis [186]. 
Finally (c) the correct choice of therapy in the elderly 
population may be the administration of an unrelated 
medication meeting the criteria of a “lean prescription” 
and Beers’s criteria [187] a careful administration of a 
related medication or the desensitization to culprit drug.
Anaphylaxis in the elderly
Anaphylaxis is a severe and potentially fatal hypersen-
sitivity reaction that can affect patients of all ages [188]. 
The elderly differ from other age groups in terms of risk 
factors because significant comorbid conditions, such 
as cardiovascular or cerebrovascular disease, hyperten-
sion and cardiac arrhythmias may occur. Moreover, in 
this population of patients compensatory mechanisms 
can be physiologically reduced or decreased due to the 
intake of antihypertensive drugs like β-blockers and ACE 
inhibitors. Also, trigger agents are usually different than 
younger patients. All these factors influence the outcome 
and the response to treatment during anaphylaxis in the 
elderly. Therefore elderly patients must be considered 
particularly vulnerable to severe anaphylaxis [189].
Campbell et  al. [143] studied presentation and man-
agement of patients with anaphylaxis who were 50 or 
65 years or older in a consecutive cohort of patients pre-
senting to an emergency department. Cardiovascular 
symptoms were more likely to occur in older patients and 
patients 50 or 65 years or older were less likely to be dis-
missed home directly from the emergency department. 
Moreover, older patients were less likely to be prescribed 
self-injectable adrenaline. Among possible triggers, food 
was the less common supposed cause of anaphylaxis in 
older patients.
A recent epidemiological study investigated trends 
in anaphylaxis admissions and fatalities by age, sex, and 
cause in England and Wales over a 20-year period [190]. 
In patients 60  years of age and older fatalities and hos-
pital admissions were most common for iatrogenic cause 
and insect sting induced anaphylaxis, while fatal out-
comes from food-induced anaphylaxis were most com-
mon in the second decade of life and very rare in adults 
older than 60 years.
In a population-based epidemiologic study conducted 
in USA using national databases, among various demo-
graphic factors, age was most significantly associated 
with anaphylaxis deaths, with a mortality rate that was 
highest in people aged between 75 and 84  years (2.04 
per million population) and that was lowest in children 
17  years or younger, and increased with advancing age 
[191].
The increased mortality and occurrence of cardiovas-
cular involvement in older patients can be due to a bigger 
age-related susceptibility to mast cell-derived mediators 
on cardiovascular system [192], and to the underlying 
comorbidities, such as coronary diseases. Mast cell-
released mediators are in fact able to induce vasospasm 
of large coronary arteries, a global reduction of myo-
cardial blood flow by influencing the vasomotor tone of 
small intramural coronary arteries, and may exert direct 
dysrhythmogenic effects [193]. Data from two thousand 
allergists treating patients with anaphylaxis in three 
European countries showed that age was an important 
risk factor for the onset of circulatory symptoms with a 
high odds ratio in older patients [194].
Moreover concomitant cardiovascular medications, 
more often prescribed to patients with advanced age, 
could negatively influence the outcome. Antihypertensive 
medication use is associated with increased organ system 
involvement during anaphylaxis and increased odds of 
hospital admission, independent of age [195].
It must be also considered that elderly patients are 
more likely to receive many different medications (such 
as antibiotics, NSAIDs), particularly parentally admin-
istered medications that cause a consequent more rapid 
exposure of allergen. Brown and collaborators found 
that, in a large cohort of people admitted to Emergency 
Departments, older age and drug (both oral and injected) 
were significantly correlated with hypotensive reactions 
[196].
There are no absolute contraindications to the pre-
scription of self-injectable adrenaline in older patients 
at risk of anaphylaxis, however some issues should be 
considered. The limited mobility or the presence of 
joint diseases, such as osteoarthritis of the hand, could 
reduce the ability to use the auto-injector. Also, a nega-
tive effect on therapeutically administered adrenaline is 
exerted by co-administration of cardiovascular medica-
tions such as β-blockers, however in patients suffering for 
heart diseases such as congestive heart failure, the use of 
β-blockers could improve the survival and the therapeu-
tic benefit can be greater than the risk of aggravating ana-
phylaxis in some patients [197]. An evaluation of patient 
on case-by-case basis together with the cardiologist is 
therefore useful.
Benefits of physical activity in the elderly with respiratory 
diseases
In geriatric populations, physical activity represents 
part of a healthy lifestyle. It favours independence and 
increases quality of life, improving aerobic capacity, mus-
cle strength, breathing pattern and cardiovascular func-
tion, with positive effects on cognitive and psychosocial 
aspects of daily living in the elderly. Furthermore, the 
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findings from some studies (but not all), support the pos-
sibility that exercise may counteract immunosenescence, 
restoring immune function in older populations and 
reducing the increased incidence and severity of infec-
tious diseases in senior subjects. It is well known, in fact, 
that exercise may influence several aspects of immune 
response, including T-cell phenotype and proliferation, 
response to vaccination, and cytokine production. How-
ever, the underlying mechanisms by which exercise can 
influence a number of cell types and immune responses 
still remains to be identified [198, 199].
Physical activity, therefore, seems to play a key role in 
avoiding the worsening of disabilities, including asthma 
and other respiratory diseases and may also represent an 
alternative therapy in patients for whom pharmacologi-
cal treatment is unavailable, ineffective, or inappropri-
ate. However, even if current data suggests that physical 
activity may be an effective and logistically easy and 
clever strategy for counteracting immunosenescence, it is 
currently underutilized in real clinical settings.
Exercise training and effects on immune and respiratory 
systems
Response to vaccines and novel antigens has been used 
as a model that may have clinical relevance to understand 
the role of exercise in modulating immune response. In 
a study by Smith et  al. [200] comparing sedentary and 
physically active elderly, the physically active group had 
significantly higher anti-KLH (keyhole-limpet hemo-
cyanin, a protein antigen) IgM, IgG, IgG1, and delayed-
type hypersensitivity responses compared with the 
sedentary older group, showing that regular physical 
activity in a senior population is associated with a more 
efficient and robust immune response to novel antigenic 
challenge [201]. In general, long term  exercise  inter-
ventions seem to show the most promising results, in 
particular as regards Exercise-related improvements 
have been reported with respect to antibody titre, T cell 
function, macrophage response, alterations of the Th1/
Th2 cytokine balance, the level of pro-inflammatory 
cytokines, and changes in naïve/memory cell ratio [200].
Pathophysiologically, in older patients with chronic 
airflow limitation as a result of asthma, COPD alone or 
in combination (ACOS), the normal age-related decline 
in lung function is amplified. Thus, mechanical ventila-
tory constraints and the perceived respiratory discomfort 
become the main factors limiting exercise [202].
Therefore, in clinical practice, middle-aged and older 
adults with moderate/severe persistent asthma are 
sometimes referred to pulmonary rehabilitation pro-
grams (PRP) that often include both breathing exercises 
and exercise training. Breathing exercises programs 
may increase muscle strength and are associated with a 
positive effect on patient health and quality of life [203]. 
The rationale underlying their participation in these pro-
grams is that the training protocol utilized and benefits 
achieved are similar to those observed in patients with 
COPD, who represent the majority of individuals referred 
to PRP [204].
To date, the majority of studies evaluating exercise 
training in asthma have been performed in children or 
young adults with mild-to-moderate persistent disease. A 
Cochrane meta-analysis of 13 randomized controlled tri-
als of exercise training for asthma concluded that training 
improves cardiopulmonary fitness in the absence of any 
changes in lung function [205] while a more recent sys-
tematic review and meta-analysis of 17 studies and 599 
patients [206] found that exercise training was shown to 
improve asthma symptoms, QoL, exercise capacity, BHR, 
EIB, and FEV1 in asthmatics. In this study, improvements 
in BHR explained part of the improvement in QoL and 
exercise capacity.
Another review showed that PRP involving exercise 
training was effective in improving exercise capacity, 
muscle force, quality of life and reducing symptoms in 
patients with COPD and asthma [207].
In patients with COPD and Asthma endurance training 
is recommended, in the form of continuous and interval 
training, having similar effects on endurance capacity, 
executed on either a bike or as walking [208]. However, 
this recommendation must take into consideration that 
endurance training may elicit an exercise-induced asthma 
attack and therefore patients must take the preventive 
treatments with Beta-2 agonists and a perform warm-
up phase of at least 15  min prior to exercise. Strength 
training is important because of the frequently atrophied 
skeletal musculature, which triggers the increase of the 
exercise-induced ventilation by early lactate acidosis 
and consequently aggravates dyspnoea during exercise. 
Patients should continue the individualized training after 
discharge from hospital in the domestic environment, 
benefitting also of training facilities, patients’ groups and 
social circumstances. Because of the frequently present 
cardio-metabolic comorbidities the assessment of the 
exercise capacity as well as an evaluation of nutrition 
should be included into a holistic therapeutical approach. 
In patients with uncontrollable fear of exercise-induced 
attacks of  asthma, additional psychological support 
should be given [208].
Functional exercise capacity is significantly improved 
after exercise training, as well as asthma symptoms and 
quality of life [203]. The efficacy of exercise training 
programs is demonstrated by a study in which, after a 
3-year follow-up of asthmatic patients, that undergone 
a supervised 10-week exercise training program, a sig-
nificant decrease in number of emergency room visits 
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was observed. The high compliance rate after the 3 years 
(68%) showed that, when exercise programs are super-
vised by health professionals, patients choose to continue 
to be physically active [209].
To evaluate the outcomes of a PRP, the well-known six-
minute walk test is often used as a measure.
As conclusion, a case report interestingly suggests that 
lifelong sports practice can be a great advantage for the 
asthmatic elderly [201]. A 86-year old athlete with a life-
long atopic asthma and COPD that competes in swim-
ming and triathlon at an international level, with an 
advanced obstructive lung disease (FEV1/FVC  =  34%), 
experienced only little perceived respiratory discomfort 
during exercise and had a peak aerobic capacity (VO2 
peak) and cycle work rate in excess of 170% predicted. 
Therefore, while this case report does not diminish the 
relative importance of ventilator constraints in dysp-
noea or exercise intolerance obstructive lung disease, it 
shows that the negative consequences of these ventilatory 
impairments can be attenuated by a constant, lifelong 
participation in high intensity exercise training with the 
impressive physiological and psychological adaptations 
associated.
Physical activity should be recommended as a sup-
plementary therapy to medication [210]. Strategies to 
increase physical and sports activity participation among 
older people should include (i) raising awareness of the 
benefits and minimize the perceived risks of physical 
activity and (ii) improving the environmental and finan-
cial access to community-based exercise programs such 
as may exist for middle-aged and older individuals with 
other chronic condition [211]. Given this evidence, an 
increase in the use of physical activity programs by the 
healthcare community may result in improved health of 
geriatric populations [198]. If positive effects will also be 
confirmed in terms of counteraction to immunosenes-
cence, exercise could be a highly cost-effective measure 
to improve human quality of life compared with other 
strategies currently being pursued.
Conclusions
The mechanisms that allow “successful” aging are related 
both to psychophysical conditions and to the immune 
system behavior. In this regard, in addition to the precise 
knowledge of the immunological mechanisms in geriatric 
age, of the lymphoproliferative responses and of the ROS 
production, the lifestyles, the diet and the physical activ-
ity should also be analysed.
Allergic diseases are often thought to be specific of 
childhood and youth, however, these conditions often 
persist into older age and can occasionally appear in 
the elderly. Several are the factors that make more com-
plicated the diagnosis and the management of allergic 
diseases in aged people, such as frailty, comorbidities and 
multiple concomitant medications. At the same time, 
nutritional deficiencies such as vitamin D deficiency, 
genetic factors, hormonal imbalances, or inflammag-
ing may affect the immune system, causing alterations of 
the responses of immunocompetent cells. All parameters 
along with the management approach proposed for dis-
eases can act as support to improve the psychophysical 
conditions of people over 65 and ensure an active and 
healthy aging.
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